How to buy Capricor Therapeutics shares
Own Capricor Therapeutics shares in just a few minutes.
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Capricor Therapeutics, Inc is a biotechnology business with stocks listed in the US. Capricor Therapeutics shares (CAPR) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$3.86 – an increase of 1.85% over the previous week. Here's how to invest if you're based in Australia.
How to buy shares in Capricor Therapeutics
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Capricor Therapeutics. Find the share by name or ticker symbol: CAPR. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Capricor Therapeutics reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$3.86, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Capricor Therapeutics, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Capricor Therapeutics. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
- Capricor Therapeutics key stats
- Compare share trading platforms
- Is Capricor Therapeutics stock a buy or sell?
- Capricor Therapeutics performance over time
- Can I short Capricor Therapeutics shares?
- Capricor Therapeutics's financials
- How volatile are Capricor Therapeutics shares?
- Does Capricor Therapeutics pay a dividend?
- Have Capricor Therapeutics shares ever split?
- Other common questions
Capricor Therapeutics share priceUse our graph to track the performance of CAPR stocks over time.
Capricor Therapeutics shares at a glance
|52-week range||US$3.13 - US$12.32|
|50-day moving average||US$3.846|
|200-day moving average||US$4.8023|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||US$-3.736|
Compare share trading platforms to buy stock
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Is it a good time to buy Capricor Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Capricor Therapeutics price performance over time
|1 week (2021-06-03)||-1.03%|
|1 month (2021-05-13)||22.15%|
|3 months (2021-03-12)||-25.48%|
|6 months (2020-12-11)||-8.10%|
|1 year (2020-06-12)||-13.06%|
|2 years (2019-06-13)||6.34%|
|3 years (2018-06-13)||-73.01%|
|5 years (2016-06-13)||-88.68%|
Capricor Therapeutics financials
|Gross profit TTM||US$-8,146,750|
|Return on assets TTM||-36.19%|
|Return on equity TTM||-72.76%|
|Market capitalisation||US$103 million|
TTM: trailing 12 months
Shorting Capricor Therapeutics shares
There are currently 1.7 million Capricor Therapeutics shares held short by investors – that's known as Capricor Therapeutics's "short interest". This figure is 1% down from 1.8 million last month.
There are a few different ways that this level of interest in shorting Capricor Therapeutics shares can be evaluated.
Capricor Therapeutics's "short interest ratio" (SIR)
Capricor Therapeutics's "short interest ratio" (SIR) is the quantity of Capricor Therapeutics shares currently shorted divided by the average quantity of Capricor Therapeutics shares traded daily (recently around 735722.03389831). Capricor Therapeutics's SIR currently stands at 2.36. In other words for every 100,000 Capricor Therapeutics shares traded daily on the market, roughly 2360 shares are currently held short.
However Capricor Therapeutics's short interest can also be evaluated against the total number of Capricor Therapeutics shares, or, against the total number of tradable Capricor Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Capricor Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Capricor Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.0785% of the tradable shares (for every 100,000 tradable Capricor Therapeutics shares, roughly 79 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Capricor Therapeutics.
Find out more about how you can short Capricor Therapeutics stock.
Capricor Therapeutics share dividends
We're not expecting Capricor Therapeutics to pay a dividend over the next 12 months.
Have Capricor Therapeutics's shares ever split?
Capricor Therapeutics's shares were split on a 1:10 basis on 4 June 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Capricor Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Capricor Therapeutics shares which in turn could have impacted Capricor Therapeutics's share price.
Capricor Therapeutics share price volatility
Over the last 12 months, Capricor Therapeutics's shares have ranged in value from as little as US$3.13 up to US$12.32. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Capricor Therapeutics's is 6.4598. This would suggest that Capricor Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Capricor Therapeutics overview
Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase II clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with COVID-19; and completed various trials investigating the use of CAP-1002 for the treatment of cardiac conditions, including heart failure and post myocardial infarction with cardiac dysfunction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in preclinical stage for the potential prevention of COVID-19. Capricor collaborates with Lonza Houston, Inc. for the development of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in Beverly Hills, California.
Frequently asked questions
More guides on Finder
How to buy Capricor Therapeutics shares
Steps to owning and managing Regency Centers shares.
How to buy The Honest Company (HNST) shares from Australia
Here's everything we know so far about The Honest Company IPO and how to buy in from Australia.
How to buy Capricor Therapeutics shares
Steps to owning and managing Applyflow shares.
Best headphones in Australia
Our expert team of reviewers pick the best headphones in Australia, with a little help from real consumer reviews.
Best fountain pens in Australia
From the best fountain pen for beginners to the top high-end model, these are the seven best fountain pens you can buy in Australia right now.
How to buy Marqeta stock from Australia when it goes public
Here's everything we know so far about the Marqeta IPO and how to buy in from Australia.
Best shower heads in Australia
We read hundreds of customer reviews to find the best shower heads you can buy online and in-store in Australia.
How to invest in the Didi Chuxing IPO from Australia
Everything we know about the Didi Chuxing IPO, plus information on how to buy in.
How to buy Robinhood stock from Australia
Robinhood is set to go public as soon as June. Here's what you need to do to buy in from Australia.
Ask an Expert